API

Apixaban (2.5mg)

Drug classification

Anticoagulant; specific subclass: direct oral factor Xa inhibitor (DOAC).

Dosage form

Film-coated oral tablet containing 2.5 mg apixaban.

API strength per dosage

Dose

Apigat 2.5 mg (apixaban) is typically used in adults for thromboprophylaxis after hip or knee replacement, or in select atrial fibrillation patients. Dose adjustments or avoidance may be needed in severe renal or hepatic impairment. Not recommended in children. Always refer to local guidelines and product information for specific indications and dosing.

Mechanism of action

Apixaban is a direct, selective inhibitor of Factor Xa, a key enzyme in the coagulation cascade. By inhibiting Factor Xa, apixaban decreases thrombin generation and thrombus development, resulting in reduced blood clot formation without directly affecting platelet aggregation.

Indications

Treatment and prevention of Blood clots

Side effects

Anemia low number of red blood cells Blood in urine Bruise Nausea Nosebleeds Hematoma

Pregnancy category

Apixaban use in pregnancy is not recommended due to limited human data and potential risk of fetal harm; use only if benefits outweigh risks.

Precautions

Bleeding risk, renal impairment, hepatic impairment, concomitant use with other anticoagulants or antiplatelets, elderly patients, body weight <60 kg, abrupt discontinuation, spinal/epidural anesthesia risk, monitor for signs of bleeding, monitor renal and hepatic function, assess for drug interactions, adherence to dosing schedule.

Contraindications

Active pathological bleeding, severe hypersensitivity to apixaban, hepatic disease with coagulopathy, lesions or conditions at increased risk of major bleeding, concomitant use with other anticoagulants (except during switching), severe renal impairment.